ABO1009-DP

BIOLOGICAL2 trials

Sponsors

Suzhou Abogen Biosciences Co., Ltd.

Conditions

COVID-19

Phase 1

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)

Suzhou Abogen Biosciences Co., Ltd.COVID-19

Start: 2022-08-22End: 2023-08-25Target: 48Updated: 2023-02-08

A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines

Suzhou Abogen Biosciences Co., Ltd.COVID-19

Start: 2022-07-08End: 2023-08-30Updated: 2023-02-08

Related Papers

Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study

Clinical and Translational Medicine2023-08-011 citations